Subscribe

Analysis EO
Jun 24, 2020
report
Analysis EO
Jun 24, 2020

Mindray, the Dominant A-share Medical Device Maker: Not a COVID-19 Speculator

► Mindray has a solid foundation for future growth based on market exposure to over 190 countries and regions. ► After so many years of acquisitions, it has become a more selling-driven model despite many efforts on R&D. COVID-19, the black swan incident to end them all, has been causing pain across a broad spectrum of industries. At the same time, it raised a collective focus on healthcare and soaring demand for medical devices, especially those life auxiliary equipment items such as respirators, biochemical analyzers and color ultrasound devices. Mindray Medical (300760:SH), as the most significant medical device provider listed on the A-market, has evolved into a thriving organism. According to the Ministry of Industry and Information Technology, this April Mindray received orders for respirators to the tune of over 10 thousand, scheduled till June. Success in a time of worldwide medical emergency follows prolonged phases of organic growth. The year of 2019 saw the company's domestic revenue grow 20% and overseas sales break through by 10%. The medical device market in China has surpassed the Japanese market, becoming the second largest globally in 2018. Indeed this golden market has always been desirable to some world-class manufacturers, such as Medtronic, Johnson & Johnson and Philips. According to China's Big Health Investment Report, 2018–2020, the domestic market size grew from CNY 126 billion in 2010 to CNY 448.4 billion in 2017 at a CAGR of 19.9%. This market size is expected to reach CNY 800 billion by using an anticipated CAGR of 21.3% from 2018 to 2020. The increased demand accelerated due to COVID-19 and tech-driven productivity triggered by the 2018 healthcare reform. Business overview Mindray mainly engages in the research, development and manufacturing processes of three fields: life information and support, in-vitro diagnosis (IVD) and medical imaging. Besides these, this Shenzhen-based company has expanded its product lines through a series of acquisitions, including orthopedics, endoscopy and other high-value consumable devices. As the largest revenue source, the life information and support business includes monitors, defibrillators, anesthetic machines, respirators, operating lamps and other life support equipment. In the IVD arena, Mindray provides reagents, analyzers, calibrators and controls. In 2015, it occupied a 0.62%  global market, according to the China Association of Medical Equipment. As for medical imaging, a tech-driven field, color ultrasound devices are the core products in the spectrum of Mindray’s portfolios. In China’s market of medical devices, one of the biggest challenges for domestic manufacturers is the competition with those big-name foreign brands. It can be taken as a general situation in all those small segments of this vast industry. The top three foreign competitors of Mindray are Philips, GE and Beckman Coulter (the US). However, some rising domestic brands with independent R&D capabilities are fast-growing. It is essential to understand this kind of growth in a more detailed way – is Mindray flowing with a general average trend or outperforming the industry benchmark? Organic growth makes profits Many indicators can assess profitability. Here in the fundamental analysis of this medical device company, ROE (Return on Equity) can explain profitability from a more comprehensive perspective. Mindray’s ROE grew from 15% in 2014 to 27.91% in 2019, with a bottom at 10% in 2015 and a peak at 47% in 2017. The last six years saw Mindray gain a fast growth from 2015 to 2017, indicated by its profitability increasing from 10% to 47%. From 2014 to 2016, when this company was busy leveraging debt to inject its liquidity for mergers and acquisitions, its net margin and the asset turnover ratio pulled the ROE performance down, especially in 2015. Into 2017, the ROE started to decrease mainly due to a fall in leverage, despite a stable increase in asset turnover and net margins. From this history, it seems that the equity multiplier and the net margin are the two drivers determining the return on equity. However, for a manufacturer, it is not common to see the profitability with sudden jumps and falls. When considering the varying equity multiplier and its previous annual reports, it is not hard to explain the volatile changes in Mindray's merger and acquisitions. It is commonly acknowledged that the acquisition is typical in the medical device arena. The rationales behind this strategy are costly R&D investment and a high entry threshold. Mindray has been playing this strategy since 2008 – the time when the financial crisis broke out. Seven years later, it acquired 12 companies, including three foreign companies and nine domestic ones. The outbound purchases help integrate those cutting-edge technologies on global-wide and local distribution channels. Those domestic acquisitions expand new business coverage in a diversification strategy. One prominent result is that Mindray has deployed subsidiaries in 32 countries in North America, Europe, Africa, Asia and Latin America and managed over 7,600 employees globally, including over 20% of researchers. Another direct impact brought by this M&A expansion strategy intertwined with high leverage is unusually high goodwill. Since 2014, the goodwill value has been over CNY 1.3 billion and accrued increasing impairment loss. Frequent acquisitions also impact overall profitability directly. In a consolidated financial report, Mindray gathers net revenues from all its subsidiaries. Additionally, the synergies out of the integrated selling distribution channels, R&D collaboration and improved production efficiency lay a positive impact on profitability. From 2014 to 2019, Mindray demonstrated strong internal-driven growth in its profitability, indicated by the five-year CAGR of net margin 9.725 and its growth margin of 0.56%. Sales-driven or R&D-driven? Undoubtedly, inorganic growth has played a considerable role in Mindray’s development path over all these years. On the other hand, from the perspective of endogenous growth, it is vital to have a more precise understanding of the critical growth driver. Only in this way can we assess how far away the ceiling and sustainability are. As a conglomerate giant in the medical device arena, Mindray has largely strengthened its distribution arms through global acquisitions and regional cooperation. Typically, there are two sales modes: direct selling and distribution. Mindray adopts selling models according to the market environment and the quality of distribution resources. The US market mainly utilizes direct selling mode to reach end-users by tendering bids and business negotiations with all-tier medical institutions, including private clinics, hospitals, pharmaceutical corporations, Group Purchase Organizations (GPOs), etc. However, on the domestic market and other developing countries' markets, a mixed strategy with an anchor on distribution is used to cover all kinds of end-users more efficiently. The brand has to gain more recognition among the company's distributors globally, indicated by the upward brand efficacy line below. Meanwhile, this company has anchored more resources in the R&D process to cement its core competency. During the last six years, the company saw a five-year CAGR of 11.8% in R&D investment and a similar 11.58% CAGR in selling expenses. However, when it comes to comparing the expenditure efficiency to create revenue, the R&D conversion (revenue / R&D expenses) shows a slightly better six-year performance with a 4.37% CAGR, compared to 4.09% CAGR in the selling expenses efficiency. Shortly after the listing on the A-share market (2014 – 2017), Mindray slowly became R&D-driven, with a 6.73% three-year CAGR of R&D efficiency rate (revenues divided by R&D investment). However, during the last three years (2017 – 2019), R&D investment sped up to 0.93% CAGR. One noteworthy thing is that, although the R&D efficiency was slowly improved in 2017 – 2019 at a CAGR less than 1%, it still reached a new historical high of 9.04% in 2019. This implies that the intellectual synergies in the R&D area by global acquisitions of advanced technologies have started to work. As another hint, Mindray’s researchers increased to 2,508 in 2019 from 1,764 in 2017, a 42.2% growth in these two years. Furthermore, this company completed 73 registrations of medical devices to 509 pieces last year. Indeed, the values created by R&D are considerable. However, in a comparative look at  growth speed, this medical device seems to be and will remain more sales-driven than R&D-driven, at least for the ensuing few years. We can assume that these companies will continue their heavy investment in R&D, regardless of expenses or capitalization. This will maintain the current sales models in all the involved markets. Considering the three-year CAGR of revenues, R&D investment and selling expenses, calculated as 21.76%, 20.75% and 14.99%, we expect growth rates of 22%, 20% and 15% for its revenue, R&D investment and selling expenses. In 2023, it is still likely to see a more powerful selling engine at 6.09% than R&D motor at 4.37%. The two data tables above show that a selling-based dynamic pushes revenue faster than R&D-based mode in more probable situations. New tech bursts out with more growth potential Medical imaging is one of three primary businesses of Mindray – but so far represents the smallest revenue source. From another perspective, it has the highest growth potential. This April, this company announced it would utilize 5G technology in smart auxiliary diagnosis and digitized workflow. For a giant medical device company like Mindray, inorganic growth is a crucial phase indicating maturity. Nevertheless, the robust technology foundation should not be neglected. It may seem that the R&D investment efficiency on revenue works more slowly right now, but it is an investment for more future possibilities.

News
Jun 8, 2020 · Simuwang
News
Jun 8, 2020 · 36Kr
News
May 18, 2020 · ifeng
Analysis EO
Apr 14, 2020
report
Analysis EO
Apr 14, 2020

China’s Bone Implants Market Rising: A Local Orthopedic Innovator Goes Public

Sanyou Medical (688085: SH), a Shanghai-based company specializing in providing innovative orthopedic implants, hit the Chinese Star Market on April 9th, bankrolled by CNY 978 million from the public market. On the issuance day, the stock price soared to CNY 36 from CNY 20.96, a 71.76% increase. This sound first-day performance not only reflects the market’s confidence towards the future potential of Chinese domestic orthopedic instruments, but also shows investors’ expectations around native manufacturers and their innovation capabilities. Founded in 2005, Sanyou Medical is a tech-driven therapy-oriented innovation company for orthopedic implants, specifically spine and trauma types. Following rich experience at Medtronic, the core R&D team established a world-class laboratory, Tytus Lab, in 2010. The Shanghai-based company received over USD 20 million in a Series A in 2014 from Qiming VC and TF Capital. In September 2017, it bankrolled another equity investment of CNY 100 million from Yingke PE.  Industry overview In the medical equipment industry, the orthopedic medical instrument segment accounts for the largest share. Orthopedic medical implants are considered the most critical subcategory. The bone prosthetic market increased to CNY 26.2 billion in 2018 from CNY 7.2 billion in 2010, more than threefold over the course of eight years.  Innovative medicine can be priced high because the patent prevents competitors from imitating the molecular structure and amino acid sequences for a certain period, typically 20 years. However, instead of patent protection, the market perceives the value of the medical equipment business as a sophisticated instrument.  The orthopedic implant materials are mostly categorized into Class 3 medical instruments. Compared to general devices, such equipment is much more complicated, and some types are placed into human bodies for a lifetime. Thus it is a strictly supervised business with regulations set at every point, from R&D to production, circulation to sales. Chinese players are catching up The spinal implant market reached CNY 7.6 billion to become the largest share of the orthopedic implants industry in 2018, surpassing the trauma implant segment, worth CNY 7.5 billion. Joint implants are the most technically demanding and also the area with the most potential, with an expected market size of CNY 15 billion in 2023. The technology of 3D printing is one primary growth driver for this business. Many world-class implant companies are leveraging this cutting-edge technique to serve more patients, such as DePuy Synthes (Johnson & Johnson family), Wright Medical, Zimmer Biomet and Smith & Nephew. In Chinese orthopedics, there has been a stereotype that Chinese companies are learning, imitating technology from overseas. Only in recent years have more Chinese doctors realized the innovative capabilities of native orthopedic equipment and the advantages of the potential cost-effectiveness. Although foreign manufacturers dominate other two markets, the trauma implants are mainly provided by Chinese companies, prominently by Naton Medical, Shanghai MicroPort (853: HKSE) and WEGO (1066: HKSE). Some giants can adopt a strategy fast, letting them sprint to success in a new business track. As one of the tier-one medical device manufacturers, Mindray (300760: SZ) acquired DragonBio at a cost of USD 35.5 million in 2012. This deal strategically helped Mindray enter the top 20 companies in the orthopedic market in 2018, with 0.53% of the domestic market. Three segments Orthopedic implants include trauma implants, spine implants and joint implants, with respective shares of 28.63%, 29.01% and 27.86% in 2018.  The development and production standards of orthopedic implants require a solid foundation in material sciences, engineering, biomedical engineering and anthropotomy. Strict supervision and long waitlists are the main barriers stopping companies from rushing into this industry. Most Chinese companies are focusing on trauma implants, with Double Medical (002901: SZ) and WEGO accounting for 5.8% and 5.5% of the domestic market, following Johnson (14.9%) and Stryker (8.4%).  In the arena of spinal implants, the usage is more correlated with medical technology. Besides medication and physical therapy, treatments for spinal illnesses include more sophisticated solutions. The percutaneous vertebroplasty (PVP) operation and percutaneous kyphoplasty (PKP) operations are two commonly known treatments. Now, as medical standards improve, more hospitals are able to provide such high-end clinical treatments. Considering the gap of PKP penetration between China (15%) and the US (40%), it is expected to see an accelerated deployment of Chinese brands in the domestic market. WEGO, Tianjin Zhengtian and Sanyou Medical are among the top six players in this niche market, set to grow at a rate of 20%-30% in the coming years. As for the market of joint implants, Chinese players are adopting a different strategy. Unlike foreign manufacturers aiming at cooperation with AAA hospitals, Chinese companies are trying to win over the market of the tier-two and tier-three cities by higher cost-effectiveness, pricing at 25%–40% the rate of imported products. Qianzhan data for 2018 shows that the tremendous demand from average hospitals and patients makes up the price gap, by giving 30% revenue growth of domestic joint implants compared to 14% of imported counterparts.  According to Frost & Sullivan, AK Medical (1789: HKSE), a 3D technology-driven joint implant provider, served over 15% of the Chinese market in 2017. In 2018, its A3 total knee system was certified by FDA510 (K), a breakthrough for a high-end medical device made in China.

Research
Mar 12, 2020 · The above information is fromWanlian Securities, with source link: www.wlzq.com.cn. Please contact this company if full report is needed.
Research
Mar 12, 2020 · The above information is fromWanlian Securities, with source link: www.wlzq.com.cn. Please contact this company if full report is needed.

It is a start of a long journey for Mindray

News
Mar 5, 2020 · 21 Finance
News
Mar 3, 2020 · The Paper
Research
Mar 2, 2020 · The above information is fromSoochow Securities, with source link: http://www.dwzq.com.cn/. Please contact this company if full report is needed.
Research
Mar 2, 2020 · The above information is fromSoochow Securities, with source link: http://www.dwzq.com.cn/. Please contact this company if full report is needed.

Self-research + merger mode will consolidate the leading position of medical devices and policies will help the company grow

Announcements
Feb 27, 2020 · Mindary
Announcements
Feb 27, 2020 · Mindary

Report on 2019 annual performance

Announcement: Click here
News
Feb 22, 2020 · Xinhua
Analysis
Feb 10, 2020 · Sina
Analysis
Feb 9, 2020
Announcements
Dec 10, 2019 · Mindary
Analysis
Nov 6, 2019 · GPLP
Analysis
Nov 6, 2019 · GPLP

Mindray Medical's Third Quarterly Report

Read more